Sinopec Shanghai Petrochemical Company Limited

  • ISIN: CNE1000004C8
  • Land: Hong Kong

Nachricht vom 29.04.2021 | 03:00

Sinopec Shanghai Petrochemical Company Limited Files 2020 Annual Report on Form 20-F


EQS-News / 29/04/2021 / 09:00 UTC+8

 

 

 

 

Sinopec Shanghai Petrochemical Company Limited

Files 2020 Annual Report on Form 20-F

 

NEW YORK, April 28, 2021 -- Sinopec Shanghai Petrochemical Company Limited (the "Company") (HKEx: 338; SSE: 600688;NYSE: SHI) announced today that its Form 20-F for the fiscal year ended December 31, 2020, filed with the United States Securities and Exchange Commission on April 29, 2020, has been posted to the Company's website at http://www.spc-ir.com.hk/eng/report.asp. The soft copy of the Company's annual report on Form 20-F could also be downloaded through its website.

 

The Company will deliver within a reasonable time after request a hard copy of its 2020 annual report on Form 20-F, including its complete audited consolidated financial statements, free of charge, to any shareholder upon request.

 

To request a hard copy of the annual report, please write to:

 

Sinopec Shanghai Petrochemical Company Limited

48 Jinyi Road, Jinshan District, Shanghai, PRC

Postal Code: 200540

Attention to: the Secretariat to the Board of Directors

 

SOURCE Sinopec Shanghai Petrochemical Company Limited

 

Related Links

http://www.spc-ir.com.hk/eng/report.asp

 

 

  • End  -

 

 

Investor and Media Enquiries:

 

PRChina Limited

Mr. Jack Liu / Alice Yip

Tel: (852) 2522 1838 / (852) 2522 1368

Email: zyliu@prchina.com.hk / ayip@prchina.com.hk

 



File: Sinopec Shanghai Petrochemical Company Limited Files 2020 Annual Report on Form 20-F

29/04/2021 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021